Precision biosciences inc stock.

That heritage lives and thrives today in Elo Life Systems, an independent company focused on food and agriculture. Precision BioSciences completed the spin-out of Elo in December 2021. At the time, gene editing as a clinical intervention to treat – let alone cure – diseases was practically science fiction. But rapid advances and ...WebNov 24, 2023 · When you look at Precision BioSciences Inc’s price-to-sales ratio at 0.93 compared to the industry median at 6.93, this company has a lower price relative to revenue compared to its peers. This could make Precision BioSciences Inc’s stock more attractive for value investors. Precision BioSciences to Present at Upcoming Sidoti Conference. DURHAM, N.C., November 10, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at ...DURHAM, N.C.--(BUSINESS WIRE)--Aug. 15, 2023-- Precision BioSciences, Inc. ... including fluctuations in our stock price, and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, ...

Nov 29, 2023 · Precision BioSciences GAAP EPS of -$0.46 misses by $0.05, revenue of $3.82M misses by $1.29M SA News Mon, Aug. 08, 2022 Precision BioSciences Q2 2022 Earnings Preview

The Precision BioSciences Inc. stock price fell by -9.31% on the last day (Wednesday, 29th Nov 2023) from $0.408 to $0.370.During the last trading day the stock fluctuated 15.44% from a day low at $0.360 to a day high of $0.416.The price has risen in 6 of the last 10 days and is up by 6.78% over the past 2 weeks. Volume has increased on …

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Stock Price Forecast The 4 analysts offering 12-month price forecasts for Precision BioSciences Inc have a median target of 2.75, with a high estimate of 3.00 and a low estimate of 2.00.DURHAM, North Carolina, April 1, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, today announced the closing of its initial public offering of 9,085,000 shares of common stock, which includes the full exercise of …Precision BioSciences (DTIL Quick Quote DTIL - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 27.5% over the past four weeks, the stock looks ...DURHAM, N.C., September 12, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the Company plans to highlight its current development programs, pipeline updates, and underlying ARCUS platform ...

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.

Precision BioSciences Inc stock is down -74.15% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives DTIL stock a score of 34 out of a possible 100.

DTIL founders never worried about cash until the meltdown. They hired too many PhDs, built fancy expensive labs with lots of promises. They never tried to trim ...Nov 8, 2023 · Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023 Nov 15 Precision BioSciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023 11 hours ago · Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “ Efficient elimination of MELAS-associated m ... Which Precision BioSciences insiders have been selling company stock? The following insiders have sold DTIL shares in the last 24 months: Alan List ($32,602.70), Dario Scimeca ($39,689.22), Derek Jantz ($38,828.94), …DURHAM, N.C.--(BUSINESS WIRE)--Nov. 1, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it will publish financial results for the third quarter 2023 and provide a ...Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “ Efficient elimination of MELAS-associated m ...

In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Precision BioSciences (DTIL - Research Report), with a price target of $2.00.The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week. (Simply Wall St.) Jan-09-23 07:30AM. Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate …Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic ... Weighted average shares of common stock ...DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso, President and Chief Executive Officer of Precision BioSciences …Find the latest Pressure BioSciences, Inc. (PBIO) stock quote, history, news and other vital information to help you with your stock trading and investing.

On Monday, Precision Biosciences Inc [NASDAQ:DTIL] saw its stock jump 2.61% to $0.45. On the same session, the stock had its day’s lowest price of $0.44, but rose to a high of $0.4695. Over the last five days, the stock has gained 30.61%. Precision Biosciences Inc shares have fallen nearly -62.35% since the year began.

DURHAM, N.C., April 20, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ...About the Company. Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.On November 7, 2023, Precision BioSciences Inc (DYAI) stock showed promising performances based on the information provided. According to data from CNN Money, the four analysts offering 12-month price forecasts for DYAI had a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00.DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023.About …For more information about our programs, see our current corporate deck.WebContact Us U.S. markets closed S&P 500 +26.83(+0.59%) Dow 30 +294.61(+0.82%) Nasdaq 14,305.03 +78.81(+0.55%) Russell 2000 1,862.64 +53.62(+2.96%) Crude Oil 74.38 -1.58(-2.08%) Gold 2,091.70... Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. ... The increase in weighted average shares of common …Web

Precision BioSciences Inc. is based in Durham, North Carolina. Stock Name, Country, Market Cap, PE Ratio. Amgen (AMGN), United States, $142.010B, 14.72. Bristol ...

Nov 29, 2023 · Precision BioSciences GAAP EPS of -$0.46 misses by $0.05, revenue of $3.82M misses by $1.29M SA News Mon, Aug. 08, 2022 Precision BioSciences Q2 2022 Earnings Preview

Nov 24, 2023 · Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform. November 28, 2023. DURHAM, N.C. -- (BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,...View Precision BioSciences, Inc DTIL investment & stock information. Get the latest Precision BioSciences, Inc DTIL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Nov 29, 2023 · View Precision BioSciences, Inc DTIL investment & stock information. Get the latest Precision BioSciences, Inc DTIL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Overall, Precision BioSciences Inc stock has a Value Grade of C, Growth Grade of C, Quality Grade of D, Momentum Grade of F Earnings Estimate Revisions Grade of C. Whether or not you should buy Precision BioSciences Inc stock will ultimately depend on your individual goals, risk tolerance and allocation.As of November 28, 2023, 4:00 PM, CST, Avidity Biosciences Inc’s stock price was $7.08. Avidity Biosciences Inc is up 14.94% from its previous closing price of $6.16. During the last market session, Avidity Biosciences Inc’s stock traded between $5.97 and $6.25. Currently, there are 74.10 million shares of Avidity Biosciences Inc stock ...Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...Jun 20, 2023 · Precision Biosciences Inc (US:DTIL) has 116 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 42,897,221 shares.

Precision BioSciences to Present at Upcoming Sidoti Conference. DURHAM, N.C., November 10, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at ...Given the current short-term trend, the stock is expected to fall -4.66% during the next 3 months and, with a 90% probability hold a price between $0.264 and ...Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023 ... Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select …Instagram:https://instagram. workers comp cost calculatorbest trading demo appbest art to invest insofi net worth Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. high leverage forex brokers usabest software for share trading Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week. (Simply Wall St.) Jan-09-23 07:30AM. Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones. axcella health We will never request to mail you a physical check for home office set up or payroll funds. If you are asked for such information, please contact our HR Team by emailing us at [email protected] to verify the legitimacy of the request. Agency recruiters interested in working with us can apply to join our RecruitiFi community.Precision BioSciences Stock (NASDAQ: DTIL) stock price, news, charts, stock research, profile.